Imipramine hydrochloride
Imipramine hydrochloride is a tricyclic antidepressant used for depression and for nocturnal enuresis in children.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It inhibits reuptake of noradrenaline and serotonin and has antimuscarinic, antihistaminic and alpha-adrenergic blocking actions that account for much of its adverse-effect profile.
Prescribing in practice
- Tricyclics are dangerous in overdose with cardiotoxicity and arrhythmia, so assess suicide risk and consider quantities supplied, and avoid in recent myocardial infarction, arrhythmias and heart block.
- Antimuscarinic effects cause dry mouth, constipation, blurred vision and urinary retention, and it can cause postural hypotension and lower the seizure threshold.
- For childhood nocturnal enuresis follow a children's formulary, treat for a limited period with review, and counsel on overdose danger to household members.
Monitoring
Monitor mood and suicidality, cardiovascular status and antimuscarinic burden, with ECG consideration where cardiac risk is present.
Counselling the patient
- Store securely away from children, as overdose is dangerous.
- Expect dry mouth, constipation or blurred vision, and rise slowly to avoid dizziness.
- Do not stop abruptly; the dose should be reduced gradually under advice.
Evidence & guidelines
Tricyclic antidepressants such as imipramine are long-established treatments, and NICE depression guidance notes their toxicity in overdose relative to newer agents.
Reference: NICE NG28 (children); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185